Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$45.76 +1.4%	$40.99	$19.45 ▼ $53.27	$2.94B	2.18	617,509 shs	573,783 shs
QURE uniQure	$14.25 -1.7%	$14.76	$4.45 ▼ $19.18	$794.25M	0.08	1.43 million shs	1.31 million shs
SRRK Scholar Rock	$39.98 -2.8%	$33.76	$6.76 ▼ $46.98	$3.90B	0.33	1.33 million shs	1.62 million shs
VKTX Viking Therapeutics	$32.10 +0.5%	$27.98	$18.92 ▼ $81.73	$3.59B	0.62	4.07 million shs	2.80 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	-2.25%	+0.53%	-1.59%	+56.74%	+4.73%
QURE uniQure	-3.27%	-0.34%	+2.04%	+0.76%	+87.34%
SRRK Scholar Rock	+0.98%	+6.56%	+20.80%	+29.96%	+372.10%
VKTX Viking Therapeutics	-0.22%	+0.98%	+22.80%	+25.35%	-37.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KYMR Kymera Therapeutics	3.1804 of 5 stars	4.5	1.0	0.0	3.3	2.5	0.0
QURE uniQure	1.8237 of 5 stars	3.5	1.0	0.0	0.6	2.5	0.6
SRRK Scholar Rock	3.151 of 5 stars	1.6	1.0	4.4	2.6	3.3	0.6
VKTX Viking Therapeutics	4.6255 of 5 stars	3.5	5.0	4.7	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYMR Kymera Therapeutics	3.05	Buy	$59.11	29.18% Upside
QURE uniQure	2.91	Moderate Buy	$37.82	165.39% Upside
SRRK Scholar Rock	3.13	Buy	$42.67	6.72% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	171.51% Upside

Current Analyst Ratings Breakdown

Latest QURE, SRRK, KYMR, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/18/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYMR Kymera Therapeutics	$47.07M	63.31	N/A	N/A	$12.90 per share	3.55
QURE uniQure	$27.12M	28.78	N/A	N/A	($0.14) per share	-101.79
SRRK Scholar Rock	$33.19M	114.37	N/A	N/A	$3.94 per share	10.15
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
QURE uniQure	-$239.56M	-$4.39	N/A	N/A	N/A	-1,077.05%	-483.87%	-34.28%	8/7/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.53	N/A	N/A	N/A	N/A	-118.22%	-82.01%	8/6/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest QURE, SRRK, KYMR, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SRRK Scholar Rock	-$0.68	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	QURE uniQure	-$0.89	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYMR Kymera Therapeutics	N/A	8.49	8.49
QURE uniQure	1.53	11.99	11.99
SRRK Scholar Rock	0.16	10.25	10.25
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYMR Kymera Therapeutics	N/A
QURE uniQure	78.83%
SRRK Scholar Rock	91.08%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
KYMR Kymera Therapeutics	16.01%
QURE uniQure	4.79%
SRRK Scholar Rock	13.30%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
QURE uniQure	500	54.78 million	52.15 million	Optionable
SRRK Scholar Rock	140	94.95 million	82.32 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

QURE, SRRK, KYMR, and VKTX Headlines

Recent News About These Companies

Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect

July 21 at 10:41 AM | zacks.com

Bank of New York Mellon Corp Has $12.52 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 21 at 3:25 AM | marketbeat.com

3 Monster Stocks in the Making to Buy Right Now

July 20 at 12:07 AM | fool.com

These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?

July 20 at 4:48 AM | fool.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Formidable Asset Management LLC

July 19 at 8:25 AM | marketbeat.com

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.

July 19 at 6:09 AM | fool.com

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

July 18, 2025 | zacks.com

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

July 17, 2025 | zacks.com

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

July 16, 2025 | prnewswire.com

H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT

July 16, 2025 | insidermonkey.com

Kintayl Capital LP Grows Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 16, 2025 | marketbeat.com

Viking Therapeutics (VKTX) Projected to Post Quarterly Earnings on Wednesday

July 16, 2025 | marketbeat.com

The Best Stocks to Invest $1,000 In Right Now

July 15, 2025 | fool.com

Concurrent Investment Advisors LLC Buys New Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 13, 2025 | marketbeat.com

Principal Financial Group Inc. Sells 30,629 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 13, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Caas Capital Management LP

July 11, 2025 | marketbeat.com

Banque Pictet & Cie SA Takes Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 11, 2025 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 10, 2025 | zacks.com

U.S. Capital Wealth Advisors LLC Sells 8,423 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 10, 2025 | marketbeat.com

Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results

July 9, 2025 | insidermonkey.com

Financial Counselors Inc. Acquires 16,823 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

QURE, SRRK, KYMR, and VKTX Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

$45.76 +0.62 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$45.71 -0.05 (-0.11%)

As of 06:58 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

uniQure NASDAQ:QURE

$14.25 -0.25 (-1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$14.34 +0.10 (+0.67%)

As of 07:54 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Scholar Rock NASDAQ:SRRK

$39.98 -1.14 (-2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$39.32 -0.66 (-1.65%)

As of 07:28 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$32.10 +0.16 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$32.38 +0.27 (+0.86%)

As of 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time